These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22053665)

  • 1. The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer.
    Avraam K; Pavlakis K; Papadimitriou C; Vrekoussis T; Panoskaltsis T; Messini I; Patsouris E
    Eur J Gynaecol Oncol; 2011; 32(5):516-20. PubMed ID: 22053665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
    Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
    Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
    Skírnisdóttir I; Seidal T
    Oncol Rep; 2012 Mar; 27(3):741-7. PubMed ID: 22159712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
    Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.
    Kupryjańczyk J; Szymańska T; Madry R; Timorek A; Stelmachów J; Karpińska G; Rembiszewska A; Ziółkowska I; Kraszewska E; Debniak J; Emerich J; Ułańska M; Płuzańska A; Jedryka M; Goluda M; Chudecka-Głaz A; Rzepka-Górska I; Klimek M; Urbański K; Breborowicz J; Zieliński J; Markowska J
    Br J Cancer; 2003 Mar; 88(6):848-54. PubMed ID: 12644821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
    Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
    Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 12. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
    Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
    Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F; Cohen C; Rahaman J; Gretz H; Cole P; Kalir T
    Cancer; 2002 Jun; 94(11):2935-40. PubMed ID: 12115382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
    Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
    Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
    Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
    Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
    Guo DH; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW; Han JH; Kim JH; Lee MH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS; Lim HY
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
    Skirnisdóttir I; Sorbe B; Seidal T
    Int J Gynecol Cancer; 2001; 11(2):147-58. PubMed ID: 11328414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.